Fig. 5: Expression profiles and clinical significance of PLK4 in DLBCL. | Cell Death & Disease

Fig. 5: Expression profiles and clinical significance of PLK4 in DLBCL.

From: Inhibition of Polo-like kinase 4 induces mitotic defects and DNA damage in diffuse large B-cell lymphoma

Fig. 5

a Gene expression analysis of PLK4 mRNA in primary DLBCL samples (GSE 2350) showed aberrantly increased levels of expression compared with B lymphocytes. b GO enrichment analysis of PLK4 co-expression genes in GSE53786. c GSEA analysis showed positive correlation between PLK4 expression and DNA replication, cell cycle, and DNA repair. d Western blot assays indicated elevated expression of PLK4 in DLBCL cell lines. e Representative immunohistochemical images showed high PLK4 expression in DLBCL patients from Shandong Provincial Hospital. Statistics of the integrated optical density value of positive staining were shown on the right. Scale bar: 50 μm. f Kaplan–Meier survival curves of DLBCL patients from GSE10846. Data were analyzed through genomicscape (http://genomicscape.com). g Lentivirus-mediated RNA interference downregulated PLK4 expression in LY8 cells. Expression of the PLK4 mRNA and protein was assessed by qRT-PCR and western blot analysis. h Lentivirus-mediated PLK4 knockdown sensitized DLBCL cells to doxorubicin. i DLBCL cells were treated with doxorubicin for 48 h and analyzed for γ-H2AX expression. PLK4-silenced cells showed enhanced phosphorylation of H2AX in a dose-dependent manner. Data are shown as the mean ± SD, n = 3. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Back to article page